Clinical Trials Browser

Phase 1 × Lymphoma, T-Cell × Brentuximab Vedotin × Clear all

NCT01309789 2017-06-28

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Phase 1 Completed

Hematologic Diseases, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic